Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 34.58% and Operating profit at -185.63% over the last 5 years
3
Flat results in Mar 25
4
Risky -
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
PLN 624 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.94
-174.62%
8.76
Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Mar 2025)
Net Profit:
-25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.2%
0%
-8.2%
6 Months
-11.74%
0%
-11.74%
1 Year
-36.63%
0%
-36.63%
2 Years
-59.35%
0%
-59.35%
3 Years
-55.8%
0%
-55.8%
4 Years
-55.8%
0%
-55.8%
5 Years
-45.21%
0%
-45.21%
Ryvu Therapeutics SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
34.58%
EBIT Growth (5y)
-185.63%
EBIT to Interest (avg)
-75.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.31
EV to EBIT
-3.48
EV to EBITDA
-3.73
EV to Capital Employed
75.89
EV to Sales
7.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2178.87%
ROE (Latest)
-129.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
16.90
25.50
-33.73%
Operating Profit (PBDIT) excl Other Income
-29.30
-41.80
29.90%
Interest
1.70
1.70
Exceptional Items
3.30
6.70
-50.75%
Consolidate Net Profit
-25.30
-35.10
27.92%
Operating Profit Margin (Excl OI)
-1,875.10%
-1,733.60%
-14.15%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -33.73% vs 68.87% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 27.92% vs -31.95% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
78.00
46.90
66.31%
Operating Profit (PBDIT) excl Other Income
-135.30
-107.20
-26.21%
Interest
3.80
0.10
3,700.00%
Exceptional Items
6.70
-3.60
286.11%
Consolidate Net Profit
-111.40
-92.10
-20.96%
Operating Profit Margin (Excl OI)
-1,869.60%
-2,522.00%
65.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 66.31% vs 20.57% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -20.96% vs -9.90% in Dec 2023
About Ryvu Therapeutics SA 
Ryvu Therapeutics SA
Pharmaceuticals & Biotechnology
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Company Coordinates 
Company Details
Leona Henryka Sternbacha 2 , KRAKOW None : 30-394
Registrar Details






